1114 GMT - Evonik posted a robust and solid set of numbers that came in line with expectations, Morgan Stanley analysts say in a research note. The German specialty-chemicals company saw both adjusted Ebitda and free-cash-flow figures ahead of Visible Alpha estimates. The company also backed its guidance for 2025 adjusted Ebitda in a range between 2.0 billion and 2.3 billion euros. "We judge that second-quarter Visible Alpha consensus [for adjusted Ebitda] at 574 million euros is likely secure given the trends in methionine but note this looks low vs normal seasonality," they say. Shares trade 1.39% higher at 20.08 euros. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
May 12, 2025 07:14 ET (11:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。